H.C. Wainwright Sticks to Their Buy Rating for Lipocine (LPCN)

By Carrie Williams

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Lipocine (LPCNResearch Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.62.

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 12.1% and a 54.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Verrica Pharmaceuticals.

Lipocine has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.

See today’s analyst top recommended stocks >>

Lipocine’s market cap is currently $106.4M and has a P/E ratio of -3.70. The company has a Price to Book ratio of 7.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.